Imbruvica® (ibrutinib) is Now Available as a Single Tablet

The FDA has approved a new formulation of IMBRUVICA^®.  All patients will need to obtain a new prescription from their physician.

Please review the important information below.

What you should know:

IMBRUVICA® is now approved by the FDA in multiple strengths as a 140, 280, 420 and 560 mg tablet.

The FDA approved the tablet formulation of IMBRUVICA^® on February 16, 2018 and it is now commercially available. The original 140-mg capsules will no longer be available after May 15, 2018.

Please see the full Prescribing Information for indications, dosage and usage.

What’s different about the package?

IMBRUVICA^® now comes in a 28-day blister pack.

What is the difference between the capsules and tablets?

IMBRUVICA^® contains the same active ingredient in capsule and tablet forms at the corresponding prescribed dose. The existing capsules are available in 70 mg and 140 mg dosage strengths; the new formulation tablets are available in 140, 280, 420 and 560 mg dosage strengths.

How do patients switch from capsule to tablet?

Physicians will need to provide patients with a new prescription for the new tablet formulation of IMBRUVICA^®.

Where should patients find more information?

Patients should talk to their doctors about their IMBRUVICA^® prescription.

For answers to common questions patients may have, please visit: www.IMBRUVICAONEPILL.com.

March 21, 2018